Refeyn

Introducing StreamlineMP! Our new software platform complements the speed of #MassPhotometry measurements with fast and consistent data analysis for specific workflows. 🔬 Beginning with our Antibody Stability Module, the platform offers specialized modules – supporting customers who need to repeatedly apply the same analysis to large datasets. The modules automate analysis, saving time and ensuring consistency. ⏱️🔄 The Antibody Stability Module enables fast, efficient analysis of the datasets obtained during antibody stability analysis, providing robust statistics on aggregation for replicate groups.  Learn more here! 👉 https://lnkd.in/gJ-tYU7f

This month, our Employee Spotlight 🤩 features Nathan Curry, Senior R&D Engineer. Today he tells us about his experience working at Refeyn! Want to join the team? Check out current job openings here ➡ https://lnkd.in/ekkAYkRX #refeyn #worktogether #biotechnology #massphotometry #career

Ready to turn up the heat 🔥 on your AAV analytics? Join our upcoming webinar! Eduard Ebberink will present a new toolset to rapidly quantify and analyze thermal stability across different AAV serotypes by combining nuclease treatment with mass photometry. Register here to gain new AAV stability insights with #MassPhotometry. 👉 https://lnkd.in/dCNkEWzK

📽️ #MeetThePortfolio - Refeyn 🔬 Led by CEO Gerry Mackay, Refeyn is redefining the molecular research landscape through mass photometry—a revolutionary technique for better measuring molecular mass, by simply shining light on single biomolecules. Refeyn's technology emerged from a breakthrough moment in 2014 when researchers from the University of Oxford discovered that a light microscope could measure individual proteins' mass. By 2018, the team had transformed this concept into a quantitative tool. Today, valued at over $250 million and with a global team of 150+, Refeyn’s instruments are empowering scientists worldwide, from pharmaceutical labs to academic research. #innovation #healthtech #lifesciences #oxford

Peter Eisenhut and colleagues from Takeda analyzed rAAV9 samples produced with two different transfection reagents: FectoVIR and Polyethylenimine. Biopotency assays found that rAAV9 samples produced with FectoVIR had higher potency. Mass-based assays like mass photometry and AUC measured the proportions of empty, full and partially filled capsids and were in excellent agreement (😉), but did not detect differences between transfection methods. On the other hand, sequencing showed that the proportion of full-length transgene loads was lower than expected from mass-based methods, and did find a difference between transfection reagents, in agreement with biopotency assays. Read the full study here! https://lnkd.in/dA4A-D_g #MassPhotometryStories #AAV 

We bring news from the cutting edge of upstream process analytics in AAV manufacturing, featuring #MassPhotometry, of course!🔬✨ In this online event, Rentschler Biopharma’s Nathan Sweeney and Cell and Gene Therapy Catapult’s Amna Anwar will present the latest findings from an ongoing project supported by InnovateUK.📊🔍 Tune in to learn about an innovative purification method coupled to mass photometry analysis that enables monitoring of empty/full AAV ratios during upstream processing with minimal time and sample consumption, addressing a significant challenge in AAV manufacturing. Register here! https://lnkd.in/g3r6KM-p

See how #MassPhotometry supports Nobel-winning research in this upcoming webinar! Arvind Pillai, from 2024 Nobel Laureate David Baker’s lab at the Institute for Protein Design, University of Washington, will talk about his work designing switchable proteins de novo.  🧬💡 These nanodevices 🦠 can be constructed to respond to molecular signals, for use in triggerable drug delivery systes, micromotors and other molecular machines. Mass photometry expedites this work by characterizing conditional oligomerization and interactions quickly and in detail.  Register here to hear the full story ➡ https://lnkd.in/dtHhCn-W

As #MassPhotometry emerges as a valuable bioanalytical technology for characterizing AAVs, people are noticing! Two recent articles mention mass photometry as one of the emerging technologies poised to address the challenges in development and manufacturing of AAV-based therapeutics. 🧬🔬 The first, by Regeneron’s Marília Barros, talks about the best strategies to quantify AAV titer. The second provides a playbook to develop effective analytical testing strategies by MilliporeSigma’s Michael Born.  In addition, a recent paper by Eduard Ebberink and colleagues demonstrates the use of mass photometry to assess the stability of empty and filled AAV preparations exposed to heat stress. 💡 Read our new blog post to learn more! https://lnkd.in/dy8SVq2Z #Bioanalytics 

We’re excited to have joined forces with Rentschler Biopharma and Cell and Gene Therapy Catapult on a new whitepaper, Improving AAV Vector Quality with In-Process Monitoring of Capsid Formation. Supported by Innovate UK, this collaboration uses mass photometry to enable in-process monitoring of full, partial, and empty capsids- helping improve the overall quality and efficiency of AAV production.   💡 𝗪𝗮𝗻𝘁 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲? Join us for an exclusive session during Informa’s BPI Fall and Viral Vectors Digital Week, where we’ll dive deeper into our findings.   🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 to explore how advanced process analytical technologies can elevate AAV manufacturing: https://lnkd.in/g3r6KM-p

Is your antibody production getting bogged down by sample-hungry aggregation analyses? #MassPhotometry can help!🧪🔬 Mass photometry delivers precise data on antibody aggregation in minutes, and with no labels or columns. Our instruments are easy to use and take up very little space, so they are perfect for quick, in-process aggregation analytics. As mass photometry works at nanomolar concentrations🧫, it can be used to assess antibody aggregation directly from, for example, IV bag samples. And if you want to check for aggregation under several different conditions, the TwoMP Auto can analyze up to 24 samples in 90 minutes⏳. Don’t get stuck analyzing aggregation! Learn more here: https://lnkd.in/dkZMitS3